{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:31:10Z","timestamp":1794022270562,"version":"4.8.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The target-hypertension (Target-HTN) trial investigated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial includes patients with suppressed plasma renin activity and elevated aldosterone levels. Lorundrostat doses of 100\u2009mg and 50\u2009mg daily significantly decreased systolic blood pressure compared to the placebo group. Cohort 2 also demonstrated a reduction in systolic blood pressure with the 100\u2009mg daily dose of lorundrostat. Lorundrostat is more selective for the inhibition of CYP11B2 versus CYP11B1, which makes it preferable to other aldosterone synthase inhibitors that inhibit cortisol synthesis, such as osilodrostat. Phase 3 trials are needed to validate the safety and efficacy of lorundrostat, and further research should be performed on other selective aldosterone synthase inhibitors such as baxdrostat, dexfadrostat, and BI 690517.<\/jats:p>","DOI":"10.1097\/crd.0000000000000665","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T09:04:06Z","timestamp":1707987846000},"page":"113-116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors"],"prefix":"10.1097","volume":"34","author":[{"given":"Jared M.","family":"Feldman","sequence":"first","affiliation":[{"name":"From the Division of Hospital Medicine, Long Island Jewish Medical Center and Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"R1-20260206","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/\/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R2-20260206","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5664\/jcsm.27878","article-title":"Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.","volume":"6","author":"Gonzaga","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"R3-20260206","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/jhh.2011.47","article-title":"Resistant hypertension, obstructive sleep apnoea and aldosterone.","volume":"26","author":"Dudenbostel","year":"2012","journal-title":"J Hum Hypertens"},{"key":"R4-20260206","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajh\/hpw003","article-title":"The role of aldosterone in obesity-related hypertension.","volume":"29","author":"Kawarazaki","year":"2016","journal-title":"Am J Hypertens"},{"key":"R5-20260206","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018.","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA"},{"key":"R6-20260206","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association.","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"R7-20260206","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/hr.2017.75","article-title":"The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins.","volume":"40","author":"Leggio","year":"2017","journal-title":"Hypertens Res"},{"key":"R8-20260206","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/pop.2021.0201","article-title":"A literate review of productivity loss associated with hypertension in the United States.","volume":"25","author":"MacLeod","year":"2022","journal-title":"Popul Health Manag"},{"key":"R9-20260206","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension.","volume":"29","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"R10-20260206","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension endorsed by the International Society of Hypertension (ISC) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"R11-20260206","first-page":"e53","article-title":"American Heart Association Professional\/Public Education and Publications Committee of the Council on Hypertension, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Genomic and Precision Medicine, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research, and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"R12-20260206","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R13-20260206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension.","volume":"30","author":"Dudenbostel","year":"2017","journal-title":"Am J Hypertens"},{"key":"R14-20260206","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors\u2014physiology and pathophysiology.","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R15-20260206","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Aldosterone and the cardiovascular system: genomic and nongenomic effects.","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology"},{"key":"R16-20260206","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature.","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"R17-20260206","doi-asserted-by":"crossref","first-page":"1097968","DOI":"10.3389\/fendo.2022.1097968","article-title":"The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patient with resistant hypertension.","volume":"13","author":"Forzano","year":"2022","journal-title":"Front Endocrinol"},{"key":"R18-20260206","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundostat for uncontrolled hypertension the target-HTN randomized clinical trial.","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"R19-20260206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.121.18761","article-title":"Primary aldosteronism: where are we now? Where to from here?","volume":"79","author":"Funder","year":"2022","journal-title":"Hypertension"},{"key":"R20-20260206","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R21-20260206","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrcardio.2017.74","article-title":"Has the SPRINT trial introduced a new blood-pressure goal in hypertension?","volume":"14","author":"Ruiz-Hurtado","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R22-20260206","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"R23-20260206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension.","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260206","first-page":"2483","article-title":"Methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease.","volume":"89","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"key":"R25-20260206","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/bcp.15713","article-title":"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium, retention, in healthy volunteers.","volume":"89","author":"Multaero","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R26-20260206","doi-asserted-by":"crossref","first-page":"1470320317717883","DOI":"10.1177\/1470320317717883","article-title":"LY3045697 Results from two randomized clinical trial of a novel inhibitor of aldosterone synthase.","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R27-20260206","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension.","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R28-20260206","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomized, controlled, phase 2 trial.","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:00:58Z","timestamp":1770390058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000665","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}